Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Src Inhibitors

Src Inhibitors SANTA MONICA SUPPLEMENT Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in Non-small Cell Lung Cancer Ramaswamy Govindan, MD he introduction of molecularly targeted therapies has injected a new sense of optimism Tin the world of Oncology. The lung cancer community should be very pleased with its contribution to this emerging field. Over the past decade, we have witnessed the introduction of two compounds that inhibit the epidermal growth factor receptor tyrosine kinase and an antibody against the vascular endothelial growth factor as a part of the standard of care in the treatment of patients with lung cancer. Naturally, these early efforts raised considerable hope, promise, and, of course, some predictable hype around targeted therapies. We have seen our share of disappointments and frustrations even within this short period of time. We are beginning to learn from our mistakes with respect to patient selection and trial design. More than 100 new drugs are currently being tested in numerous clinical trials involving patients with lung cancer. To make sense of what is going on this world of molecularly targeted therapies as it relates to lung cancer, leading experts around the world have been meeting annually http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Thoracic Oncology Wolters Kluwer Health

Src Inhibitors

Dy, Grace
Journal of Thoracic Oncology , Volume 5 – Dec 1, 2010
Download PDF
64 pages

Loading next page...
 
/lp/wolters-kluwer-health/src-inhibitors-25YU74Rjnf

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

ISSN
1556-0864

Abstract

SANTA MONICA SUPPLEMENT Summary of the Proceedings from the 10th Annual Meeting of Molecularly Targeted Therapy in Non-small Cell Lung Cancer Ramaswamy Govindan, MD he introduction of molecularly targeted therapies has injected a new sense of optimism Tin the world of Oncology. The lung cancer community should be very pleased with its contribution to this emerging field. Over the past decade, we have witnessed the introduction of two compounds that inhibit the epidermal growth factor receptor tyrosine kinase and an antibody against the vascular endothelial growth factor as a part of the standard of care in the treatment of patients with lung cancer. Naturally, these early efforts raised considerable hope, promise, and, of course, some predictable hype around targeted therapies. We have seen our share of disappointments and frustrations even within this short period of time. We are beginning to learn from our mistakes with respect to patient selection and trial design. More than 100 new drugs are currently being tested in numerous clinical trials involving patients with lung cancer. To make sense of what is going on this world of molecularly targeted therapies as it relates to lung cancer, leading experts around the world have been meeting annually

Journal

Journal of Thoracic Oncology – Wolters Kluwer Health

Published: Dec 1, 2010

There are no references for this article.